Roivant announced positive Phase 2 results for mosliciguat in treating Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD), meeting primary and secondary endpoints with significant improvements. This data positions mosliciguat as a potential first-in-class treatment for a high-mortality condition with limited options, leading to the initiation of a Phase 3 trial.
Roivant's announcement details highly successful Phase 2 clinical trial results for mosliciguat in PH-ILD, a severe and underserved condition. The drug demonstrated a remarkable 56.3% placebo-adjusted reduction in PVR, along with significant improvements in 6MWD and NT-proBNP, exceeding expectations. This is a major positive catalyst for Roivant, as it validates their drug development strategy and addresses a critical unmet medical need, potentially leading to a significant market opportunity. The initiation of a Phase 3 trial immediately following these results signals confidence and a fast-track development path, creating a long-term opportunity for the company and its investors, while short-term sentiment should be strongly positive.